Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 2, 2022 (4 years ago)

Moxifloxacin Ophthalmic Solution

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviation: discontinue of stability support for product.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LLC 94 Worldwide Drive, Dawsonville, GA 30534, NDC 72189-0334-05

Affected NDC 72189-0334-05

Compare with the code on your package — it is the most precise check available.

Drug: Moxifloxacin Category: Eye Drops & Ophthalmic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Moxifloxacin
NDC 72189-0334
HYDROCHLORIDE 5 mg/mL Solution/ Drops
Ophthalmic
Direct Rx Rx
Recalling firm
Direct Rx
NDC code
72189-0334-05
Origin
GA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0101-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Moxifloxacin recalls

See all

Other recalls by Direct Rx

All 2022 recalls
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Direct Rx NDC 61919-482-30 D-0617-2026
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Direct Rx NDC 61919-0482-30 D-0568-2025
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Direct Rx NDC 61919-422-30 D-0567-2025
Class II · Moderate risk

Ciprofloxacin Ophth Solution

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect Direct Rx NDC 61919-795-05 D-0364-2025